Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Diagnostic Performance and Prognostic Value of 18F-Fluoroazomycin Arabinoside (FAZA) Positron Emission Tomography/Magnetic Resonance Imaging (PET/MR) in Patients With Kidney Graft Fibrosis

NCT05638308 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT05638308
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05638308 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Diagnostic Performance and Prognostic Value of 18F-Fluoroazomycin Arabinoside (FAZA) Positron Emission Tomography/Magnetic Resonance Imaging (PET/MR) in Patients With Kidney Graft Fibrosis
Lead sponsor
University Health Network, Toronto
Phase
Not applicable
Overall status
Completed
Start date
May 26, 2018
Completion date
June 13, 2023
Enrollment
31 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

kidney graft fibrosis